Induction of antiidiotypic immune response with autologous T-cell vaccine in patients with multiple sclerosis

Bull Exp Biol Med. 2008 Jul;146(1):133-8. doi: 10.1007/s10517-008-0237-9.


Patients with different forms of multiple sclerosis were treated with a vaccine consisting of myelin-reactive T cells. It was found that after this treatment, lymphocytes from patients acquired the capacity to generate antiidiotypic proliferative response directed towards myelin-reactive T cells. The serum concentration of IFN-gamma decreased about 2-fold 1.5-2.0 years after the start of vaccine therapy, whereas the concentration of IL-4 increased 2-3 fold. Myelin-reactive proliferative activity of peripheral blood mononuclear cells also decreased. The results of the 2-year follow-up study revealed no side effect of T-cell vaccination in patients with cerebrospinal form of multiple sclerosis and demonstrated its possible clinical efficiency in the treatment of this disease at early stages.

MeSH terms

  • Adolescent
  • Adult
  • Cell Proliferation
  • Humans
  • Immune System Phenomena*
  • Interferon-gamma / blood
  • Interferon-gamma / immunology
  • Interleukin-4 / blood
  • Interleukin-4 / immunology
  • Middle Aged
  • Multiple Sclerosis* / immunology
  • Multiple Sclerosis* / therapy
  • Myelin Sheath / immunology
  • T-Lymphocytes / cytology
  • T-Lymphocytes / immunology*
  • Vaccines* / immunology
  • Vaccines* / therapeutic use
  • Young Adult


  • Vaccines
  • Interleukin-4
  • Interferon-gamma